Elan continues to attract buy recommendations, with NCB Stockbrokers joining the ranks of those tipping it for investors. NCB believes Elan is undergoing a metamorphosis from a drug delivery and technology licensing company to a global integrated specialist pharmaceutical operation. This change is a move into higher margin proprietary pharmaceuticals which should drive further expansion. The company is due to launch three new drugs towards year-end, Neurobloc, Ziconotide and Frovatriptan, which will also fuel expansion. Elan's shares are currently trading at a discount to its peers in the market and as its risk profile is now reduced, NCB is forecasting a six to 12 month price target range of $60.